- Home
- SLRX vs DRMA Comparison
SLRX vs DRMA Comparison
Compare SLRX & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- DRMA
- Stock Information
- Founded
- SLRX N/A
- DRMA 2014
- Country
- SLRX United States
- DRMA United States
- Employees
- SLRX N/A
- DRMA N/A
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- SLRX Health Care
- DRMA Health Care
- Exchange
- SLRX Nasdaq
- DRMA Nasdaq
- Market Cap
- SLRX 3.6M
- DRMA 3.3M
- IPO Year
- SLRX N/A
- DRMA 2021
- Fundamental
- Price
- SLRX $3.87
- DRMA $5.38
- Analyst Decision
- SLRX
- DRMA Strong Buy
- Analyst Count
- SLRX 0
- DRMA 1
- Target Price
- SLRX N/A
- DRMA $10.00
- AVG Volume (30 Days)
- SLRX 319.3K
- DRMA 79.8K
- Earning Date
- SLRX 11-13-2025
- DRMA 11-12-2025
- Dividend Yield
- SLRX N/A
- DRMA N/A
- EPS Growth
- SLRX N/A
- DRMA N/A
- EPS
- SLRX N/A
- DRMA N/A
- Revenue
- SLRX N/A
- DRMA N/A
- Revenue This Year
- SLRX N/A
- DRMA N/A
- Revenue Next Year
- SLRX N/A
- DRMA N/A
- P/E Ratio
- SLRX N/A
- DRMA N/A
- Revenue Growth
- SLRX N/A
- DRMA N/A
- 52 Week Low
- SLRX $3.64
- DRMA $4.55
- 52 Week High
- SLRX $108.00
- DRMA $23.70
- Technical
- Relative Strength Index (RSI)
- SLRX 36.35
- DRMA 50.49
- Support Level
- SLRX $3.83
- DRMA $4.55
- Resistance Level
- SLRX $4.19
- DRMA $5.22
- Average True Range (ATR)
- SLRX 0.31
- DRMA 0.44
- MACD
- SLRX 0.09
- DRMA 0.02
- Stochastic Oscillator
- SLRX 13.43
- DRMA 58.04
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.